Announcements Trials
Browse Landscape

Phase

Phase 2 279Phase 1 180Phase 1/2 109Phase 3 81Phase EARLY_PHASE1 12Phase 2/3 5Phase NA 4Phase 4 3

Status

Recruiting 17Completed 5Active not recruiting 5Unknown 3Terminated 2Not yet recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 3OTHER 1NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 3Other solid neoplasm 2

Conditions

Carcinoma, Non-Small-Cell Lung 2Parkinson Disease 4, Autosomal Dominant Lewy Body 1Mesothelioma 1Advanced or Metastatic Solid Malignancies 1Advanced Solid Tumor 1

Interventions

Cisplatin 22Fluorouracil 21Radiotherapy 18Gemcitabine 17Docetaxel 16Oxaliplatin 15Paclitaxel 14Carboplatin 13Capecitabine 13Bevacizumab 13Leucovorin 11Cyclophosphamide 11Irinotecan 10Drug Therapy 10Cytarabine 9Saline Solution 7Magnetic Resonance Spectroscopy 7Letrozole 7Dexamethasone 7Rituximab 6Nivolumab 6Methotrexate 6Exercise 6Etoposide 6Electroporation 6Doxorubicin 6pembrolizumab 5Pemetrexed 5Metformin 5Melphalan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2/3 × Completed × pembrolizumab × Clear all
NCT04619797 2026-02-03

SKYSCRAPER-06

Hoffmann-La Roche

Phase 2/3 Completed
542 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04887870 2025-10-10

Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study

Mirati Therapeutics Inc.

Phase 2/3 Completed
52 enrolled

Advanced or Metastatic Solid Malignancies

NCT02784171 2024-12-10

Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

Canadian Cancer Trials Group

Phase 2/3 Completed
520 enrolled 16 charts 1 FDA
Other solid neoplasmThoracic

Mesothelioma

NCT05809336 2023-04-12

Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors

Beijing Friendship Hospital

Phase 2/3 Completed
172 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT01905657 2021-10-06

MK-3475-010

Merck Sharp & Dohme LLC

Phase 2/3 Completed
1,034 enrolled 16 charts
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡